Applied Genetic Technologies (AGTC) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Applied Genetic Technologies (AGTC) Tops Q2 EPS by 11c
February 11, 2015 8:00 AM EST
GAINESVILLE, Fla., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the second quarter ended December 31, 2014.
"We are rapidly advancing our lead programs X-linked retinoschisis (XLRS) and achromatopsia (ACHM) toward Phase I/II clinical trials and expect to see initial clinical results for both programs during the second half of 2015," said Sue Washer, President and CEO. "We are also advancing preclinical studies for our product candidate addressing X-linked retinitis... More
